Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy
European Journal of Cancer2018Vol. 102, pp. 31–39
Citations Over TimeTop 16% of 2018 papers
Ayman Madi, David J. Fisher, Tim Maughan, James Colley, Angela Meade, Julie Maynard, Vikki Humphreys, Harpreet Wasan, Richard Adams, Shelley Idziaszczyk, Rebecca Harris, Richard Kaplan, Jeremy P. Cheadle
Related Papers
- → Functional Characterization of 21 Allelic Variants of Dihydropyrimidine Dehydrogenase Identified in 1070 Japanese Individuals(2018)44 cited
- → Potential added value of combined DPYD/DPD genotyping and phenotyping to prevent severe toxicity in patients with a DPYD variant and decreased dihydropyrimidine dehydrogenase enzyme activity(2021)4 cited
- → Dihydropyrimidine Dehydrogenase Genotyping and Phenotyping for 5- Fluorouracil Dysmetabolism: Moving Towards Personalized Chemotherapy in Patients with Cancer(2009)2 cited
- → Near Miss or Standard of Care? DPYD Screening for Cancer Patients Receiving Fluorouracil(2020)1 cited
- → Evolution of Dihydropyrimidine Dehydrogenase (DPD) Diagnostics in A Single Center in A Time-Period of Seven Years(2017)